Canada's Topigen Pharmaceuticals has gained $25 million in venture support for its clinical programs in respiratory disorders. The round brings the biotech's total financing to $71 million to date. The investment is earmarked for Phase II clinical programs relating to its lead products, TPI 1020, a small-molecule drug in development for Chronic Obstructive Pulmonary Disease and TPI ASM8, its RNA-inhibiting therapeutic for asthma.
In this round, new investors NovaQuest and MMV Financial join the existing venture investors: BDC Venture Capital, Desjardins Venture Capital, Caisse de DÃ©pot et Placement du QuÃ©bec, T2C2/BIO 2000 and Lothian Partners 27 SICAR. Additional funds and investors may be added to this financing.
- see the release for more information
ALSO: Quaker BioVentures has led a $13 million Series C round for EKR Therapeutics. Launched last summer, EKR markets a pain drug. Release